

Tumor Volume
(Mean ± SEM mm3)
2000
1500
1000
500
0
7 11 15 19 23 27 31 35 39 43 47
Days Post Inoculation
end of dosing
Human IgG + Vehicle Control
retifanlimab 10 mg/kg IP Q5D
ANTIBODY Y 10 mg/kg IP Q5D
Compound 9 10 mg/kg PO BID
retifanlimab + ANTIBODY Y
retifanlimab + Compound 9
ANTIBODY Y + Compound 9
retifanlimab + ANTIBODY Y + Compound 9

FIG. 1



Percent survival
100
80
60
40
20
0
0 10 20 30 40 50 60 70 80 90
Study Day
Human IgG + Vehicle Control
retifanlimab + ANTIBODY Y
retifanlimab + Compound 9
ANTIBODY Y + Compound 9
retifanlimab + ANTIBODY Y + Compound 9

FIG. 2.